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Background: The C-Pulse System is an implantable, non-blood contacting device
designed to provide long-term counterpulsation therapy for patients with
advanced heart failure. Results from a recently completed a 20 patient IDE
prospective study demonstrated improvements in NYHA class and quality of life
with a low incidence of adverse events. We describe our single center experience
in a subgroup of patients undergoing implantation of the C-pulse system who
showed signs of myocardial recovery allowing for successful discontinuation of
device support.
Methods: Between July 2010 and April 2012, six patients underwent implantation
of the C-Pulse device at a single institution under the feasibility study. Safety
endpoints included death, aortic disruption, neurologic events, myocardial infarc-
tion, and major infection at 6 months. Quality of life was assessed using the
MLWHF and the KCCQ.
Results: Mean age was 50 years (range 34-71) and 83% were male. All patients
were NYHA class III at baseline, with non-ischemic etiology in 83% (5/6). Two
patients were inotrope dependent. There were no deaths, no neurologic events,
aortic disruptions, myocardial infarctions, or mediastinal infections. One patient
was transitioned to an implantable LVAD at 97 days post implant for worsening
heart failure symptoms. Two patients remain clinically stable on device support
(1178 and 982 days). Three patients showed clinically signiﬁcant improvement
allowing for discontinuation of device support with explantation of the percu-
taneous lead (mean duration of support 659 days, range 534-793 days). In the
patients weaned, mean ejection fraction increased from 18.3% to 29.3% with a
mean reduction in LVEDD of 1.1cm. Mean follow up time post-weaning was 335
days (range 52-565 days). There have been no readmissions for recurrent heart
failure.
Conclusions: Long-term counterpulsation therapy with the C-pulse system has shown
feasibility, preliminary safety and efﬁcacy in patients with moderate to severe
ambulatory heart failure, with the potential for sufﬁcient myocardial recovery to allow
for discontinuance of device support in a signiﬁcant number of patients in our single
center experience.
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Background: The MitraSpacer (Cardiosolutions, Inc.) is a novel approach to
address mitral regurgitation by introducing a dynamic spacer with characteristics
that constantly adjust to the instantaneous hemodynamics of the mitral apparatus and
left atrium (LA). The purpose of this study was to evaluate the safety of the
MitraSpacer within the mitral valve apparatus in the Yucatan miniature swine
model.
Methods: Four (4) Yucatan miniature swine were enrolled in this study. Through a
left thoracotomy, the shaft of the MitraSpacer was introduced into the left ven-
tricular (LV) apex and advanced in to the LA avoiding the chordae tendineae. Once
the device was in place, the balloon was partially ﬁlled to the desired volume with an
iopromide/saline mix introduced by a subcutaneous access port. After implantation, all
animals were survived up to 90 days.
Results: Following implantation, device performance was assessed by ﬂuoroscopy
and echocardiography. The volume within the balloon shifted during the cardiac cycle
in all cases following the direction of blood ﬂow and applied pressure. All enrolled
animals survived up to 90 days for terminal imaging and tissue harvest. Echocar-
diographic data showed no change in LV ejection fraction from baseline to 90 days,
61.251.7% and 58.093.6% (p¼0.2) respectively, and slight changes in LA and LV
volumes consistent with the rate of growth of the animal over time. Cardiac perfor-
mance was maintained and no functional or structural changes to the mitral apparatus
were observed over 90 days by serial imaging. In addition, there were no observations
of disruption in LV diastolic function, pulmonary vein inﬂow, or tricuspid
regurgitation.
Conclusions: In a healthy porcine model, the feasibility of chronic (up to 90 days)
placement of the MitraSpacer was demonstrated. In contrast to currently used
mitral valve repair/replacement devices, the subcutaneous port of this device
allows for post-implantation adjustment of the balloon volume, making it poten-
tially ideal for treatment of patients with mitral regurgitation due to left ventricular
dysfunction.B24 JACC Vol 64/11/Suppl BTCT-81
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Background: Commercially available in-vitro cardiac simulators offer testing op-
portunities for transcatheter valve therapies (TVT) as they are able to replicate the
physiological ﬂow and pressure accurately. These simulators lack the anatomical
similarity needed for some transcatheter device testing as well as training and teaching
physicians. The ex-vivo simulator combines the anatomical similarity with physio-
logical ﬂow and pressure signatures.
Methods: The left side of a porcine heart was incorporated into a circulatory loop and
driven by a pulsatile pump. Compliances were added to achieve physiological pressure
and ﬂow signatures and native movement of the mitral (MV) and aortic (AV) heart
valve. Pressure transducers acquire the aortic, ventricular and mitral real-time pres-
sures. A ﬂow meter measures the cardiac output of the simulator. Access sites at aorta,
atrium and apex allow the insertion of TVT devices as well as endoscopic visualization.
Results: The pressure differences over the MV and AV are comparable to physio-
logical values. The characteristics of the valves such as oriﬁce area as well as the
duration of opening and closing comply with those in native hearts.Conclusions: The ex-vivo simulator reliably duplicates the movement of the MV and
AV. Hence it is a cost-effective, and user-centric bench top model suitable for testing
TVT and training and teaching of TVT methods. Advantages are the time associated
with each trial especially in comparison with animal tests and the low experimental
costs while still being able to test in an intact heart.
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Background: Surgical ventricular reconstruction has been used to treat heart failure
patients with large ventricular aneurysms. This study assessed the feasibility and ef-
ﬁcacy of performing minimally invasive thoracoscopically assisted transcatheter
ventricular restoration (TCVR) in an anteroseptal ovine infarction model.
Methods: Anteroseptal scar was achieved by percutaneous coil-occlusion of the left
anterior descending artery. Two months after occlusion, TCVR was performed in ﬁve
sheep via a minimal left thoracotomy and right external jugular catheter intervention.
Under endoscopic and ﬂuoroscopic guidance, trans-interventricular septal puncture
was performed at the epicardial border of the scar using a proprietary needle, and a
guidewire was externalized via a snare placed in the right ventricle from the right
external jugular vein. An internal anchor with a tether was inserted over the wire and
positioned on the right ventricular septum and an external anchor was deployed on the
LV anterior epicardium. Serial pairs of anchors were placed and LV walls were pli-
cated to completely exclude the scar through apposition of the antero-lateral wall to
the septum and exclusion of the intervening wall segment. LV performance was
evaluated before (baseline) and six weeks after device implantation by echo.
Results: All animals survived with no procedural or device-related complications.
Compared to baseline, LV end-systolic volume was decreased by 46% (34.016.8 vs.
baseline 62.020.9ml, p< 0.001) and end-diastolic volume decreased by 32%
(60.918.3 vs. baseline 89.518.0, p< 0.01) 6 weeks post TCVR. Ejection fraction
was signiﬁcantly increased by 14% (469% vs. baseline 329%, p< 0.01) and stroke
volume was preserved (26.93.9 vs. baseline 27.54.6ml, p¼NS).
Conclusions: A thoracoscopically assisted TCVR procedure is safe and effective. A
signiﬁcant and presumably clinically important reduction in LV volume can bej September 13–17, 2014 j TCT Abstracts/Heart Failure Therapies
